What is Lifesci Capital's Estimate for AVBP FY2025 Earnings?

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Stock analysts at Lifesci Capital decreased their FY2025 earnings per share estimates for shares of ArriVent BioPharma in a research note issued to investors on Monday, June 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings per share of ($3.99) for the year, down from their prior forecast of ($3.97). The consensus estimate for ArriVent BioPharma's current full-year earnings is ($2.74) per share. Lifesci Capital also issued estimates for ArriVent BioPharma's FY2026 earnings at ($4.03) EPS.

Other analysts have also recently issued reports about the stock. Jones Trading started coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a "buy" rating and a $40.00 price target for the company. Guggenheim reaffirmed a "buy" rating and issued a $45.00 target price on shares of ArriVent BioPharma in a research report on Tuesday. HC Wainwright raised their target price on ArriVent BioPharma from $39.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, May 14th. Oppenheimer boosted their price target on ArriVent BioPharma from $39.00 to $44.00 and gave the stock an "outperform" rating in a research report on Tuesday. Finally, Wall Street Zen downgraded shares of ArriVent BioPharma from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.00.

ArriVent BioPharma Stock Down 1.3%

ArriVent BioPharma stock opened at $22.80 on Thursday. The firm has a fifty day moving average of $21.47 and a 200-day moving average of $23.07. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $36.37. The firm has a market capitalization of $779.99 million, a P/E ratio of -6.05 and a beta of 1.26.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($1.24).

Institutional Investors Weigh In On ArriVent BioPharma

Several hedge funds and other institutional investors have recently bought and sold shares of AVBP. Rhumbline Advisers grew its position in shares of ArriVent BioPharma by 9.1% during the fourth quarter. Rhumbline Advisers now owns 36,690 shares of the company's stock worth $977,000 after buying an additional 3,069 shares in the last quarter. New York State Common Retirement Fund boosted its stake in ArriVent BioPharma by 34.6% during the 4th quarter. New York State Common Retirement Fund now owns 7,783 shares of the company's stock valued at $207,000 after acquiring an additional 2,000 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in ArriVent BioPharma by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 206,379 shares of the company's stock worth $5,498,000 after acquiring an additional 4,011 shares in the last quarter. Swiss National Bank acquired a new position in ArriVent BioPharma during the 4th quarter worth $703,000. Finally, Intech Investment Management LLC bought a new stake in shares of ArriVent BioPharma in the 4th quarter worth about $394,000. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.